PROGNOSTIC FACTORS OF TUMORAL PROCESS IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER
https://doi.org/10.17650/2220-3478-2014-0-2-33-40
Abstract
New prognostic factors for disseminated colorectal cancer (dCRC) are being investigated in this article.
Subjects and methods. In this study we have analyzed three clinical groups. First group – 60 patients with dCRC had not specifical therapy. Second group – 200 patients had specifical therapy, but without identification of prognostic and predictive markers. And third group – 93 patients had individual therapy which was based on prognostic and predictive markers of each patient.
Results. Definition of prognostic factors (TS, TP, DPD, Ercc-1, СОХ-2, MSI, KRAS) in patients with dCRC allowed to prescribe optimal specific therapy and improve results of treatment.
Conclusion. Investigation of prognostic markers allowed to differentiate prognostic groups among dCRC patients. Investigation of prognostic factors in patients with intermediate prognosis allows to improve treatment outcome and improve number of liver surgery.
About the Authors
Ye. Yu. Zorina
City Clinical Oncology Dispensary, Saint-Petersburg
Russian Federation
Russian Federation
R. V. Orlova
Medical Faculty, Saint-Petersburg State University
Russian Federation
Russian Federation
References
1. Мерабишвили В. М. Злокачественные новообразования в Санкт-Петербурге. СПб., 2007.
2. Гарин А. М., Базин И. С. Злокачественные опухоли пищеварительной системы. М., 2003. C. 96–98.
3. Bergamo N. A., Rogatto S. R., Poli-Frederico R. C. Comparative genomic hybridization analysis detects frequent overrepresentation of DNA sequences at 3q, 7p, and 8q in head and neck carcinomas. Cancer Genet Cytogenet 2000 May; 119(1):48–55.
4. Зорина Е. Ю., Орлова Р. В. Молекулярно-генетические различия в опухолевой ткани у пациентов с диагнозом диссеминированного колоректального рака при благоприятном и неблагоприятном течении заболевания. Клинико-лабораторный консилиум 2013;2–3(46):77–9.
5. Зорина Е. Ю., Орлова Р. В. Оптимизация режимов химиотерапии диссеминированного колоректального рака на основе анализа комбинации молекулярных предиктивных маркеров. Клинико-лабораторный консилиум 2013;2–3(46):79–81.
6. Орлова Р. В. Обоснование принципов лекарственного лечения диссеминированных солидных опухолей. СПб., 2004.
7. Имянитов Е. Н., Хансон К. П. Молекулярная онкология: клинические аспекты. СПб., 2007.
8. Braun M. S., Richman S. D., Quirke P. et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690–8.
9. Lievre A., Bachet J. B., Boige V. et al. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–9.
Review
Views:
705
Email this article 